Skip to content
banner-news_01

Group News

  • Aspen confirms non-binding term sheet on manufacture and sale of an Aspen- branded COVID-19 vaccine throughout Africa
    on 30.11.2021

    Durban, South Africa - JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is pleased to confirm that one of its wholly-owned South African subsidiaries, Aspen SA Operations (Pty) Limited (“Aspen SA”), has confirmed a non-binding term sheet with Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica NV, two of the Janssen Pharmaceutical […]

  • Aspen welcomes Kenyan President Uhuru Kenyatta to its Gqeberha manufacturing site
    on 24.11.2021

    Aspen Chairman Kuseni Dlamini (far left) welcoming Kenyan President His Excellency President Uhuru Kenyatta (centre) together with Aspen’s Stavros Nicolaou, Senior Executive Strategic Trade (far right) Gqeberha, South Africa - Aspen, a global multinational specialty pharmaceutical company, earlier today welcomed Kenyan President, His Excellency President Uhuru Kenyatta, to its world class flagship […]

  • Minister Ebrahim Patel opens Aspen’s world class general anaesthetic manufacturing line
    on 25.10.2021

    Stephen Saad, Aspen Group Chief Executive (left) and Honorable Minister of Trade, Industry and Competition, Mr Ebrahim Patel at the unveiling of Aspen's general anaesthetics manufacturing line in Gqeberha, South Africa Gqeberha, South Africa - Aspen, a global multinational specialty pharmaceutical company, earlier today hosted the Honorable Minister of Trade, Industry and Competition, Mr Ebrahim Patel who […]

  • Aspen increases revenue from continuing operations by 12% to R37,8 billion
    on 01.09.2021

    Johannesburg - JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is pleased to report the following salient financial results for the year ended 30 June 2021: Revenue from continuing operations increased by 12% to R37,8 billion (June 2020: R33,7 billion*);Normalised EBITDA from continuing operations increased by 3% to R9,9 billion (June […]

  • Stephen Saad discusses the J&J vaccine release with eNCA’s Sally Burdett
    on 27.07.2021

    Aspen confirmed on 26 July 2021 that the first supplies to South Africa of the Johnson & Johnson COVID-19 vaccines, from the new API source located in Europe, were being released to Johnson & Johnson from its flagship Gqeberha-based manufacturing site. These vaccines will be further distributed throughout South Africa in line with the various distribution arrangements between Johnson & Johnson, […]

Scroll To Top